Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Authors
Vale, CBurdett, S
Rydzewska, L
Albiges, L
Clarke, Noel W
Fisher, D
Fizazi, K
Gravis, G
James, N
Mason, M
Parmar, M
Sweeney, C
Sydes, M
Tombal, B
Tierney, J
Affiliation
MRC Clinical Trials Unit at UCL, London, UKIssue Date
2015-12-21
Metadata
Show full item recordAbstract
Results from large randomised controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged. In order to investigate the effects of these therapies and to respond to emerging evidence, we aimed to systematically review all relevant trials using a framework for adaptive meta-analysis.Citation
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. 2015: Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(15)00489-1PubMed ID
26718929Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(15)00489-1
Scopus Count
Collections
Related articles
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
- Authors: James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK, STAMPEDE investigators
- Issue date: 2016 Mar 19
- Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
- Authors: Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher JM, Burdett S, Chen YH, Clarke NW, Fizazi K, Gravis G, James ND, Liu G, Matheson D, Murphy L, Oldroyd RE, Parmar MKB, Rogozinska E, Sfumato P, Sweeney CJ, Sydes MR, Tombal B, White IR, Tierney JF, STOPCAP Collaboration
- Issue date: 2023 Jul
- Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
- Authors: Landre T, Guetz GD, Chouahnia K, Fossey-Diaz V, Taleb C, Culine S
- Issue date: 2019 Aug
- Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
- Authors: Jakob T, Tesfamariam YM, Macherey S, Kuhr K, Adams A, Monsef I, Heidenreich A, Skoetz N
- Issue date: 2020 Dec 3
- Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
- Authors: Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C
- Issue date: 2018 Jun